Hyperprolactinemia: Etiology, diagnosis, and management

被引:88
作者
Mah, PM [1 ]
Webster, J [1 ]
机构
[1] No Gen Hosp, Endocrine Ctr, Sheffield S5 7AU, S Yorkshire, England
关键词
hyperprolactinemia; prolactinoma; dopamine agonists; bromocriptine; cabergoline; pregnancy;
D O I
10.1055/s-2002-36709
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Hyperprolactinemia is the most common endocrine disorder of the hypothalamic-pituitary axis. A prolactinoma is the most common cause of chronic hyperprolactinemia once pregnancy, primary hypothyroidism, and drugs that elevate serum prolactin levels have been excluded. Patients can present with hypogonadism, infertility, galactorrhea, osteopenia, and mass effects of the tumor. When hyperprolactinemia is confirmed, a cause for the disorder needs to be sought. This involves a careful history and examination, followed by laboratory tests and diagnostic imaging of the sella turcica. The goals of treatment are to normalize prolactin levels, restore gonadal function, and reduce the effects of chronic hyperprolactinemia. Dopamine agonists are the treatment of choice for the majority of patients. Transsphenoidal surgery is usually reserved for patients who are intolerant of or resistant to dopamine agonists or when hyperprolactinemia is caused by nonprolactin-secreting tumors compressing the pituitary stalk. Cabergoline has been shown to be more effective and better tolerated than bromocriptine. However, there are more data on the safety of the latter drug during pregnancy and bromocriptine, therefore, remains the treatment of choice in hyperprolactinemic women wishing to conceive.
引用
收藏
页码:365 / 373
页数:9
相关论文
共 45 条
[1]   DOPAMINE AGONISTS AND PITUITARY-TUMOR SHRINKAGE [J].
BEVAN, JS ;
WEBSTER, J ;
BURKE, CW ;
SCANLON, MF .
ENDOCRINE REVIEWS, 1992, 13 (02) :220-240
[2]   FACTORS IN THE OUTCOME OF TRANS-SPHENOIDAL SURGERY FOR PROLACTINOMA AND NONFUNCTIONING PITUITARY-TUMOR, INCLUDING PREOPERATIVE BROMOCRIPTINE THERAPY [J].
BEVAN, JS ;
ADAMS, CBT ;
BURKE, CW ;
MORTON, KE ;
MOLYNEUX, AJ ;
MOORE, RA ;
ESIRI, MM .
CLINICAL ENDOCRINOLOGY, 1987, 26 (05) :541-556
[3]   PROGRESSIVE TRABECULAR OSTEOPENIA IN WOMEN WITH HYPERPROLACTINEMIC AMENORRHEA [J].
BILLER, BMK ;
BAUM, HBA ;
ROSENTHAL, DI ;
SAXE, VC ;
CHARPIE, PM ;
KLIBANSKI, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (03) :692-697
[4]  
Biller BMK, 1999, INT J FERTIL WOMEN M, V44, P74
[5]  
Biller BMK, 1999, J REPROD MED, V44, P1075
[6]  
CAMANNI F, 1998, CLIN ENDOCRINOL, P148
[7]   Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients [J].
Colao, A ;
Di Sarno, A ;
Landi, ML ;
Scavuzzo, F ;
Cappabianca, P ;
Pivonello, R ;
Volpe, R ;
Di Salle, F ;
Cirillo, S ;
Annunziato, L ;
Lombardi, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (06) :2247-2252
[8]  
CORENBLUM B, 1993, FERTIL STERIL, V59, P671
[9]  
Delitala G, 1998, CLIN ENDOCRINOL, P138
[10]   The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas [J].
Di Sarno, A ;
Landi, ML ;
Marzullo, P ;
Di Somma, C ;
Pivonello, R ;
Cerbone, G ;
Lombardi, G ;
Colao, A .
CLINICAL ENDOCRINOLOGY, 2000, 53 (01) :53-60